Saleh Ahmed, Yee Chee-Seng, Acquah Aba, Gordon Caroline, Reynolds John A
Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Rheumatology Department, Faculty of Medicine, Mansoura University, Mansoura, Arab Republic of Egypt.
Rheumatology (Oxford). 2025 May 1;64(5):2749-2755. doi: 10.1093/rheumatology/keae672.
Cutaneous vasculitis (CV) is common in SLE, but the epidemiology and risk factors remain unclear. We aimed to identify the trends and risk factors for CV in patients with SLE over a period of 20 years.
The Birmingham Lupus Cohort is an observational longitudinal cohort of SLE patients. Patients were enrolled within 3 years of meeting their fourth ACR criterion. Disease activity, laboratory test results and treatment records were collected. A multivariable shared frailty Cox proportional hazard model was used to identify clinical, laboratory and treatment-related variables associated with the development of CV.
We included 392 patients: 95.7% were female. The median (interquartile range) duration of follow-up was 9.2 (5.1-14.7) years. CV occurred in 27% of SLE patients, of whom 43.3% had two or more CV events. This study demonstrated a marked decline in the incidence rates of CV, decreasing from 34.4% (95% CI 29.7, 39.3) during the first 3 years after enrolment to 2.1% (95% CI 0.05, 11.5) after 18 years of follow-up. Development of CV was associated with RP, constitutional, mucocutaneous, musculoskeletal, haematological and cardiovascular involvement, anti-Sm antibodies, anti-dsDNA, and hypocomplementemia. However, the use of AZA and antimalarials was inversely associated with the development of CV. Patients with CV were more likely to develop at least one item of organ damage.
The incidence rates of CV in SLE decreased over the follow-up period and CV is associated with defined clinical, serological and treatment-related factors.
皮肤血管炎(CV)在系统性红斑狼疮(SLE)中很常见,但流行病学和危险因素仍不清楚。我们旨在确定20年间SLE患者CV的趋势和危险因素。
伯明翰狼疮队列是一个对SLE患者进行观察的纵向队列。患者在符合第四次美国风湿病学会(ACR)标准的3年内入组。收集疾病活动、实验室检查结果和治疗记录。使用多变量共享脆弱性Cox比例风险模型来确定与CV发生相关的临床、实验室和治疗相关变量。
我们纳入了392例患者,其中95.7%为女性。随访的中位(四分位间距)时间为9.2(5.1 - 14.7)年。27%的SLE患者发生了CV,其中43.3%有两次或更多次CV事件。本研究表明CV的发病率显著下降,从入组后前3年的34.4%(95%可信区间29.7,39.3)降至随访18年后的2.1%(95%可信区间0.05,11.5)。CV的发生与雷诺现象(RP)、全身症状、黏膜皮肤症状、肌肉骨骼症状、血液系统症状和心血管系统受累、抗Sm抗体、抗双链DNA抗体以及低补体血症有关。然而,使用硫唑嘌呤(AZA)和抗疟药与CV的发生呈负相关。发生CV的患者更有可能出现至少一项器官损害。
在随访期间,SLE患者中CV的发病率下降,且CV与特定的临床、血清学和治疗相关因素有关。